As the COVID-19 pandemic impacted many clinical trials, sponsors were forced to quickly re-evaluate potential solutions to mitigate risks and keep trial participants safe. Continuing trials in Idiopathic Pulmonary Fibrosis (IPF) research was especially difficult as patients living with chronic lung diseases may face a greater likelihood of complications if …
![](https://ddblog.labcorp.com/wp-content/uploads/2021/01/Lungs-Clinical-Trials-Covance-450x300.jpg)